uniQure Announces Financial Results for Second Quarter 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Chardan Capital Trims PT on uniQure (QURE) to $35; Notes Uncertainty of Glybera in the U.S.
August 27, 2015 12:02 PM EDTChardan Capital trims its price target on uniQure N.V. (Nasdaq: QURE) from $40 to $35 and maintains a Buy rating following Q2 results and update issued earlier.
Analyst Gbola Amusa noted that the lowered price target stems from (1) uncertainty for Glybera... More
uniQure (QURE) Reports Q2 Loss of EUR0.51/Share
August 27, 2015 6:07 AM EDTuniQure (NASDAQ: QURE) reported Q2 EPS of (EUR0.51), versus (EUR0.87) reported last year. Revenue for the quarter came in at EUR1.04 million, versus EUR1.62 million reported last year.
Pipeline Updates
Hemophilia B: Dosing is underway in the Phase I/II study of AMT-060 in hemophilia B and the Company anticipates... More